TY - JOUR
T1 - Treatment of autologous peripheral blood stem cell transplantation combined with interferon for chronic myelogenous leukemia
AU - Chai, Yen
AU - Yi, Liang Cai
AU - Liu, Ying
AU - Zhang, Lian Sheng
PY - 2006/6/10
Y1 - 2006/6/10
N2 - Aim: To observe the effect of autologous peripheral blood stem cell transplantation (APBSCT) combined with interferon on chronic myelogenous leukemia (CML), so as to evaluate the therapeutic effect of mobilization regimen of the peripheral blood stem cell, tolerance of pretreatment regimen and the post-transplanted hematogenic restoration. Methods: A total of 7 CML patients without heart, lung, liver, rend or other functional damage of organs treated at the Second Hospital of Lanzhou University between August 1999 and December 2003 were selected. The patients were 31 to 57 years old with the 36 years as the median. The mobilization regimen was composed of cytoxa (CTX), recombinant human granulocyte colony-stimulating factor and dexamethasone. The pretreatment regimen was CTX, cytosine arabinoside and 6-thioguanine. The peripheral blood stem cell was collected with CS-3000 Plus cell separator and frozen in the refrigerator at -80 °C low temperature to perform the monocyte count and CD34+ cell detection. Then the cell was fast thawed at 42 °C water bath and transfused back quickly through the vein. The interferon 3×106 u was hypodermic injected for the treatment of anti-leukemia after transplantation, and once the next day. The time for hematogenic restoration (neutrophil to 0.5×109 L-1, platelet to 20×109 L-1), the complication after pretreatment (infection, hemorrhagic cystitis, hepatica veno-occlusive disease, interstitial pneumonia and so on) and cytogenitic reaction as well as survival state were observed. Results: All the 7 patients were involved in the result analysis. 1The 7 patients appeared hematogenic restoration. The time to recovery 0.5×109 L-1 for neutrophil was from the 9th to 14th days after transplantation (the 10th day for the median), and for platelet to 20×109 L-1 was from the 8th to 15th days after transplantation (the 10th day for the median). 2There were 4 patients with ulcer of oral mucosa, 2 with diarrhea, 2 with increase of glutamic pyruvic transaminase and 6 with infected fever. There were no serious complication such as hemorrhagic cystitis, hepatic veno-occlusive disease, and interstitial pneumonia and no transplant-related mortality. 3 Four cases appeared partial or complete cytogenetic reaction, and 4 of them survived for more than 5 years. Conclusion: The characteristics of the APBSCT include fast hematogenic restoration, little complication and high successful rate, and the α-interferon after APBSCT can appear graft versus host reaction, which can prevent relapse. The APBSCT combined with interferon can prolong the survival time of the patients with CML For the patients without hemopoietic stem cells, the APBSCT should be performed during CR1 period.
AB - Aim: To observe the effect of autologous peripheral blood stem cell transplantation (APBSCT) combined with interferon on chronic myelogenous leukemia (CML), so as to evaluate the therapeutic effect of mobilization regimen of the peripheral blood stem cell, tolerance of pretreatment regimen and the post-transplanted hematogenic restoration. Methods: A total of 7 CML patients without heart, lung, liver, rend or other functional damage of organs treated at the Second Hospital of Lanzhou University between August 1999 and December 2003 were selected. The patients were 31 to 57 years old with the 36 years as the median. The mobilization regimen was composed of cytoxa (CTX), recombinant human granulocyte colony-stimulating factor and dexamethasone. The pretreatment regimen was CTX, cytosine arabinoside and 6-thioguanine. The peripheral blood stem cell was collected with CS-3000 Plus cell separator and frozen in the refrigerator at -80 °C low temperature to perform the monocyte count and CD34+ cell detection. Then the cell was fast thawed at 42 °C water bath and transfused back quickly through the vein. The interferon 3×106 u was hypodermic injected for the treatment of anti-leukemia after transplantation, and once the next day. The time for hematogenic restoration (neutrophil to 0.5×109 L-1, platelet to 20×109 L-1), the complication after pretreatment (infection, hemorrhagic cystitis, hepatica veno-occlusive disease, interstitial pneumonia and so on) and cytogenitic reaction as well as survival state were observed. Results: All the 7 patients were involved in the result analysis. 1The 7 patients appeared hematogenic restoration. The time to recovery 0.5×109 L-1 for neutrophil was from the 9th to 14th days after transplantation (the 10th day for the median), and for platelet to 20×109 L-1 was from the 8th to 15th days after transplantation (the 10th day for the median). 2There were 4 patients with ulcer of oral mucosa, 2 with diarrhea, 2 with increase of glutamic pyruvic transaminase and 6 with infected fever. There were no serious complication such as hemorrhagic cystitis, hepatic veno-occlusive disease, and interstitial pneumonia and no transplant-related mortality. 3 Four cases appeared partial or complete cytogenetic reaction, and 4 of them survived for more than 5 years. Conclusion: The characteristics of the APBSCT include fast hematogenic restoration, little complication and high successful rate, and the α-interferon after APBSCT can appear graft versus host reaction, which can prevent relapse. The APBSCT combined with interferon can prolong the survival time of the patients with CML For the patients without hemopoietic stem cells, the APBSCT should be performed during CR1 period.
UR - http://www.scopus.com/inward/record.url?scp=33747343646&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:33747343646
SN - 1671-5926
VL - 10
SP - 124
EP - 126
JO - Chinese Journal of Clinical Rehabilitation
JF - Chinese Journal of Clinical Rehabilitation
IS - 21
ER -
